Indaptus Therapeutics, Inc. Basic Shares Outstanding (Weighted Average)
Indaptus Therapeutics, Inc. (INDP) reported Basic Shares Outstanding (Weighted Average) of 116.13 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-13
- Indaptus Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 116.13M shares, a 20099.44% increase year-over-year.
- Indaptus Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 10.96M shares, a 2101.04% increase year-over-year.
- Indaptus Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 1.80M shares, a 360.55% increase year-over-year.
- Indaptus Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 997.04K shares, a 193.54% increase year-over-year.
- Indaptus Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 966.12K shares, a 189.14% increase from fiscal 2024.
- Indaptus Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 334.13K shares, a 96.02% decline from fiscal 2023.
- Indaptus Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 8.40M shares, a 1.68% increase from fiscal 2022.
- Indaptus Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2022 was 8.26M shares, a 101.98% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 3 month as first filed | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 6 month as first filed | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 9 month as first filed | Weighted Average Number of Shares Outstanding, Basic 12 month | Weighted Average Number of Shares Outstanding, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 116.13M shares 10-Q · filed 2026-08-13 | 64.11M shares 10-Q · filed 2026-08-13 | 42.96M shares derived: average of 3 quarters · filed 2026-08-13 | 32.47M shares derived: average of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | 10.96M shares 10-Q · filed 2026-05-15 | 6.38M shares derived: average of 2 quarters · filed 2026-05-15 | 4.58M shares derived: average of 3 quarters · filed 2026-05-15 | 3.58M shares derived: average of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | 1.80M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | 1.40M shares derived: average of 2 quarters · filed 2026-03-17 | 1.12M shares derived: average of 3 quarters · filed 2026-08-13 | 966.12K shares 10-K · filed 2026-03-17 | ||||
| 2025-09-30 | 997.04K shares 10-Q · filed 2025-11-12 | 785.98K shares derived: average of 2 quarters · filed 2026-08-13 | 689.17K shares 10-Q · filed 2025-11-12 | 614.98K shares derived: average of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | 574.92K shares 10-Q · filed 2026-08-13 | 539.54K shares 10-Q · filed 2026-08-13 | 487.63K shares derived: average of 3 quarters · filed 2026-08-13 | 450.64K shares derived: average of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | 497.79K shares 10-Q · filed 2026-05-15 | 14.10M shares 10-Q · filed 2025-05-14 | 443.99K shares derived: average of 2 quarters · filed 2026-05-15 | 409.21K shares derived: average of 3 quarters · filed 2026-05-15 | 383.19K shares derived: average of 4 quarters · filed 2026-05-15 | |||
| 2024-12-31 | 390.18K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | 364.92K shares derived: average of 2 quarters · filed 2026-03-17 | 344.99K shares derived: average of 3 quarters · filed 2026-03-17 | 334.13K shares 10-K · filed 2026-03-17 | 9.36M shares 10-K · filed 2025-03-13 | |||
| 2024-09-30 | 339.66K shares 10-Q · filed 2025-11-12 | 9.51M shares 10-Q · filed 2024-11-12 | 322.40K shares derived: average of 2 quarters · filed 2025-11-12 | 315.45K shares 10-Q · filed 2025-11-12 | 8.83M shares 10-Q · filed 2024-11-12 | 4.37M shares derived: average of 4 quarters · filed 2025-11-12 | ||
| 2024-06-30 | 305.14K shares 10-Q · filed 2025-08-13 | 8.54M shares 10-Q · filed 2024-08-12 | 303.34K shares 10-Q · filed 2025-08-13 | 8.49M shares 10-Q · filed 2024-08-12 | 5.72M shares derived: average of 3 quarters · filed 2025-08-13 | 6.39M shares derived: average of 4 quarters · filed 2025-08-13 | ||
| 2024-03-31 | 8.44M shares 10-Q · filed 2025-05-14 | 8.42M shares derived: average of 2 quarters · filed 2025-05-14 | 8.41M shares derived: average of 3 quarters · filed 2025-05-14 | 8.41M shares derived: average of 4 quarters · filed 2025-05-14 | ||||
| 2023-12-31 | 8.40M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | 8.40M shares derived: average of 2 quarters · filed 2025-03-13 | 8.40M shares derived: average of 3 quarters · filed 2025-03-13 | 8.40M shares 10-K · filed 2025-03-13 | ||||
| 2023-09-30 | 8.40M shares 10-Q · filed 2024-11-12 | 8.40M shares derived: average of 2 quarters · filed 2024-11-12 | 8.40M shares 10-Q · filed 2024-11-12 | 8.37M shares derived: average of 4 quarters · filed 2024-11-12 | ||||
| 2023-06-30 | 8.40M shares 10-Q · filed 2024-08-12 | 8.40M shares 10-Q · filed 2024-08-12 | 8.36M shares derived: average of 3 quarters · filed 2024-08-12 | 8.33M shares derived: average of 4 quarters · filed 2024-08-12 | ||||
| 2023-03-31 | 8.40M shares 10-Q · filed 2024-05-08 | 8.34M shares derived: average of 2 quarters · filed 2024-05-08 | 8.31M shares derived: average of 3 quarters · filed 2024-05-08 | 8.30M shares derived: average of 4 quarters · filed 2024-05-08 | ||||
| 2022-12-31 | 8.27M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | 8.27M shares derived: average of 2 quarters · filed 2024-03-13 | 8.26M shares derived: average of 3 quarters · filed 2024-03-13 | 8.26M shares 10-K · filed 2024-03-13 | ||||
| 2022-09-30 | 8.26M shares 10-Q · filed 2023-11-06 | 8.26M shares derived: average of 2 quarters · filed 2023-11-06 | 8.26M shares 10-Q · filed 2023-11-06 | 8.26M shares derived: average of 4 quarters · filed 2023-11-06 | ||||
| 2022-06-30 | 8.26M shares 10-Q · filed 2023-08-14 | 8.26M shares 10-Q · filed 2023-08-14 | 8.27M shares derived: average of 3 quarters · filed 2023-08-14 | 7.25M shares derived: average of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | 8.26M shares 10-Q · filed 2023-05-11 | 8.27M shares derived: average of 2 quarters · filed 2023-05-11 | 6.91M shares derived: average of 3 quarters · filed 2023-05-11 | 5.67M shares derived: average of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | 8.28M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | 6.23M shares derived: average of 2 quarters · filed 2023-03-17 | 4.80M shares derived: average of 3 quarters · filed 2023-03-17 | 4.09M shares 10-K · filed 2023-03-17 | ||||
| 2021-09-30 | 4.18M shares 10-Q · filed 2022-11-10 | 3.06M shares derived: average of 2 quarters · filed 2022-11-10 | 2.69M shares 10-Q · filed 2022-11-10 | |||||
| 2021-06-30 | 1.94M shares 10-Q · filed 2022-08-08 | 1.94M shares 10-Q · filed 2022-08-08 | ||||||
| 2021-03-31 | 1.94M shares 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |